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Antisense oligonucleotides for ICAM-1 attenuate reperfusion
injury and renal failure in the rat
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Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury
and renal failure in the rat. The leukocyte adhesion molecule ICAM-1 is
implicated in ischemic renal reperfusion injury. We tested the utility of an
TCAM-1 antisense oligodeoxyribonucleotide (ODN) with lipofectin, six
hours prior to 30 minutes of bilateral renal ischemia in the rat. We
measured ICAM-1 expression by immunohistochemistry and Western
blot. Our antisense ODN showed a specific ICAM-1 surface expression
inhibition in vitro. We then assessed ICAM-1 expression, leukocyte
infiltration, serum creatinine, serum urea concentration, and renal histol-
ogy in rats subjected to renal ischemia and controls. Serum creatinine and
urea concentrations 12 and 24 hours post-ischemia were increased in
saline treated and reverse ODN treated rats, compared to antisense ODN
treated or sham operated rats (P < 0.05). Western blotting showed
decreased ICAM-1 protein in antisense ODN-treated kidneys, compared
to reverse ODN treated and saline treated ischemic controls (P < 0.05).
Antisense ODN also ameliorated the ischemia-induced infiltration of
granulocytes and macrophages (P < 0.05), and resulted in less cortical
renal damage as assessed by a quantitative pathological grading scale (P <
0.05), compared to reverse ODN or saline treatment. Thus, antisense
ODN for ICAM-1 protected the kidney against ischemic renal failure. The
clinical applicability of these findings extends beyond ischemic acute renal
failure.
Reperfusion injury involves activated leukocytes with an en-
hanced adhesiveness to the endothelium [1, 2]. In the kidney, the
adherent leukocytes plug capillaries, generate free radicals and
proteolytic enzymes, and release cytokines [3]. The vasa recta
become congested, capillary perfusion is impaired [4], and endo-
thelial permeability is increased [5]. Adhesion molecule mediated,
neutrophil endothelial binding is inherent to this process [6, 7].
The leukocyte 2 integrin complex (CD11/CD18) interacts with
the endothelial ligand intercellular adhesion molecule-i
(ICAM-1) [8]. The initial rolling of neutrophils is mediated by the
selectins, while CD11/CD18-ICAM-1 interactions are responsible
for leukocyte adhesion and diapedesis [9]. Studies in liver, brain,
and myocardium [10—14] showed that ICAM-1 is up-regulated
during ischemia-reperfusion. Antibodies against either CD1 if
CD18 or ICAM-1 prevented tissue damage and protect organ
function in other studies [10, 15, 16]. Antibodies against both
CD11/CDII8 and ICAM-1 ameliorated ischemia-induced tissue
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injury and protected renal function [17, i8]. However, antibody
treatment has inherent problems that could be circumvented with
antisense oligonucleotides. We tested the hypothesis that ICAM-1
antisense oligonucleotides can inhibit ICAM-1 expression in the
ischemic kidney, prevent neutrophil adhesion and infiltration, and
thereby ameliorate ischemia-induced renal failure.
Methods
Oligonucleotides
Phosphorothioate oligodeoxyribonucleotides (ODN) were pur-
chased (Tib Molbiol, Berlin, Germany). We selected an antisense
ODN (ISIS 1939) against the human 3' untranslated region
derived from the rat ICAM sequence RSICAM and the human
ICAM-1 sequence HSICAMO1 (European Molecular Biology
Laboratories data base, Heidelberg, Germany) [19, 20]. For the
rat experiments, we compared rat and human sequence data and
used the rat homologue to ISIS 1939 (5' ACC GGA TAT CAC
ACC TIC CT 3'). The reverse ODN sequence was used as
control. We used a cationic lipid solution (Lipofectin; GIBCO
BAL, Life Technologies, Hamburg, Germany) to enhance the
ODN uptake. In the in vitro experiments, lipofectin was added five
minutes prior to the ODN application, while in the animal
experiments ODN and lipofectin were added together.
Animal protocol
Male Sprague-Dawley rats (Ivanovas, Kisslegg, Germany) aged
12 weeks, were maintained in cages at 24 2°C and were given
tap water and a standard rat diet (C-1000; Altromin, Lage,
Germany) containing 0.2% sodium by weight. They were fasted 12
hours before surgery. After thiohexital (Brevimytal; Bayer, Le-
verkuesen, Germany) anesthesia, a cathether was placed in the
right femoral artery and vein. Lipofectin solution (1 ml) contain-
ing antisense ODN, reverse ODN control, lipofectin control, or
0.9% saline control were administered to four groups of 12 rats
each, via the venous catheter six hours prior to ischemia. We also
included a sham-operated saline-injected group and a sham-
operated lipofectin-injected group to control for any operative, or
lipofectin-induced effects. Finally, we included a group of rats that
were sacrificed to determine basal ICAM-1 expression in non-
anesthetized, nonmanipulated rats. Ischemic injury was induced in
anesthetized rats by clamping the left and right renal hila with
microaneurysm clamps for 30 minutes after a bilateral flank
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In vitro procedures and ELISA for ICAM-1
For the in vitro testing of ODN and lipofectin concentrations we
used cultured human umbilical vein endothelial cells, which were
isolated from umbilical cords by chymotrypsin treatment as
described previously [211. For measurement of surface expression
The excised kidneys were divided with forceps and scissors into
medulla and cortex. The tissue slices were treated with ice cold
buffer (10 mrvi Tris-HCI pH 7.4, 100 mvi NaCI, 300 mivi sucrose, I
mM EDTA, 0.2 mrvi PMSF, I jig/mI leupeptin, 0.5% Triton X-100,
0.2% NaN3) and immediately homogenized. The homogenate was
then spun at 13 000 g for five minutes and the supernatant was
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incision. Blood samples (0.5 ml) for urea and creatinine determi- of ICAM-1 on cultured endothelial cells we used a modified
nation were obtained from the femoral arterial cathether at —6, 0, ELISA protocol [21].
12, and 24 hours after reperfusion. Rats were killed under chloral
hydrate anesthesia and the kidneys removed at 12 and 24 hours. Western blotting
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Fig. 4. A. (opposite page, bottom) Immunohistochemical staining of isch-
emic kidneys for granulocytes (arrows on representative cells) with saline
treatment (left), antisense ODN treatment (middle), and reverse ODN
treatment (right) (representative of 30 photomicrographs). B. The number of
granulocyte infiltrates qualitatively expressed as no infiltrates (s), 1 to 4
infiltrates (Lu, or  5 infiltrates (•) from these immunohistochemical
sections (vessels counted N > 50; *p < 0.05). Antisense ODN decreased
granulocyte infiltration.
collected. After determination of protein content, the immuno-
blotting was carried out as previously published [22]. Briefly, 25
jxg of each sample were run on a 10% polyacrylamide gel and
electro-blotted onto a Poly-Screen PVDF Transfer Membrane
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(New England Nuclear, Boston, MA, USA). The membrane was
then treated according to a commercially available protocol
(Serva, Heidelberg, Germany). The membrane was incubated
with a monoclonal antibody directed against rat ICAM-1 (clone
1A29; Medac, Hamburg, Germany), followed by a goat antimouse
antibody, linked to alkaline phosphatase (Dianova, Hamburg,
Germany). After equilibration of the blot in assay buffer (pH
10.0), the detection was carried out by incubation with the
AP-substrate CDP Star (Serva, Heidelberg, Germany) for five
minutes.
Dot blot and densitometry were used for quantitation of
ICAM-i expression. A total of 0.1 j.tg of each sample was dotted
onto Poly-Screen PVDF Transfer-Membrane. The further treat-
ment of the membrane was performed according to the above
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—6 0 12 24Fig. 1. Effect of sense and antisense oligonucleotides on JCAM-l expression
in rat kidney. A. (opposite page, top) Immunohistochemical staining for
ICAM-l in ischemic animals with saline treatment (left, arrows on tubular
cell and vascular endothelial cell surface), antisense oligonucleotides
(ODN) treatment (middle) and reverse ODN treatment (right, arrows on
same structures) (representative of 30 photomicrographs). B. Densitomet-
nc data from these sections (N = 30, *P < 0.05). Symbols are: (LI) no
treatment; () anti-sense ODN; () sense ODN. Ischemia induced a
marked increase in ICAM-l expression along the endothelial cell lining of
the blood vessels and in the peritubular area. Antisensc ODN prevented
the ischemia-induced increase in IcAM-1 expression, both in the vascu-
lature and in the penitubular area. Reverse ODN had no effect.
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Fig. 3. Effect of antisense and reverse ODN on serum creatinine concentra-
tions (A) and urea concentrations (B) before and after ischemia. Saline
treated animals showed a significant increase in creatinine and urea
concentrations, peaking at 24 hours. Antisense ODN prevented the
ischemia-induced increase in creatinine and urea concentrations. Reverse
ODN had no effect. Symbols are: (0) ischemia; (+) ischemia + AS-ODN;(A) ischemia + rev-ODN; (LI) sham-operated. *p < 0.05 compared to
ischemia without treatment.
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Fig. 2. A. Western blot for ICAM-1 in the cortex
and in the medulla of kidneys from saline treated
ischemic animals (left), antisense ODN treated
animals (middle), and reverse ODN treated
animals (right) (representative experiment of 12
kidneys in each group). B. Densitometric data
from these Western blots (N = 12 in each
group). Ischemia induced a marked increase in
ICAM-1 expression both in the renal cortex (LI)
and in the renal medulla (s). Treatment with
antisense ODN prevented the ischemia-induced
increase in ICAM-1 expression both in the
vasculature and in the peritubular area. Reverse
ODN had no effect. *P < 0.05.
described protocol (Serva, Heidelberg, Germany). The signal was
quantified densitometrically with a Biorad (Freiburg, Germany)
video densitometer 620. The signals were then integrated and the
results were expressed in arbitrary units.
Immunohistochemistiy and pathology
Immunohistochemistry was carried Out as previously described
[23]. For immunohistochemical staining, the sections were incu-
bated with the monoclonal antibody anti-rat ICAM-1, clone 1A29,
(Medac, Hamburg, Germany), monoclonal antibody anti-rat
monocytes, clone ED 1, (Camon, Wiesbaden, Germany) mono-
clonal antibody anti-rat granulocytes, clone His 48, (Dianova,
Hamburg, Germany) and diluted in RPMI (Seromed, Heidelberg,
Germany) for 30 minutes at room temperature in a humid
chamber. After washing with TBS, the sections were incubated
with a rabbit anti-mouse bridging antibody (Dako, Hamburg,
Germany). The immunoreactivity was visualized with an alkaline
phosphatase antialkaline phosphatase (APAAP) complex (Dako).
For detection and development we used the neufuchsin-naphthol-
As-Bi-phosphate substrate (Merck, Darmstadt, Germany) as de-
scribed.
Semiquantitative data on the ICAM-1 expression were ob-
tained by measuring the gray values of the film autoradiograms
using the microdensitometrical program of the IBAS 2.5 (Kon-
tron, Konstanz, Germany) according to a previously published
microdensitometric method [23]. The autoradiograms were digi-
tized directly via a television camera (CCD 72/MTi-camera) on a
screen, allowing the measurement of an entire section at once.
Transmissions as well as optical densities were obtained utilizing
post-processing programs.
The degree of leukocyte infiltration was determined by visually
counting the stained granulocytes and monocytes, respectively, in
the perivascular areas across kidney sections, as described previ-
ously [23]. To quantify the results we used a grading scale in which
0 indicated that no infiltrating cells were present, I indicated that
one to four infiltrating leukocytes were identified, and 2 indicated
infiltrates of 5 or more cells. The infiltrates were expressed as %
of the vessels analyzed. Kidneys from six animals in each group
were used for this purpose. Multiple sections were examined, so
that at least 50 separate vessels were evaluated from each of the
three groups.
Six half kidneys from each group at both 12 and 24 hours were
sectioned, fixed in formalin, and stained with hematoxylin and
eosin as described for our laboratory previously [24]. Without
knowledge of the regimens, sections from each kidney were
evaluated by a pathologist. Tubular necrosis was assessed with a
quantitative grading scale (0 to 3) corresponding to none, mild,
moderate, or severe necrosis as outlined elsewhere [241. Cell
swelling, vacuolization, nuclear pyknosis, necrosis and cellular
infiltrate were evaluated.
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Statistical analysis
Statistical analysis was carried out on a Macintosh II computer
(Apple Inc., Cupertino, CA, USA) with a commercially available
program (Statview; Cricket Software Inc., Philadelphia, PA,
USA). The results (mean SEM) represent duplicate measure-
ments made on seven to ten separate rats from each group.
Nonparametric (Wilcoxon test) and parametric (2 way ANOVA)
were used as appropriate. P c 0.05 was considered significant.
Results
To select the most effective lipofectin concentration for the
gene transfer, we examined lipofectin concentrations ranging
from 0.1 to 5 mg/mg DNA on TNF-a induced expression of
ICAM-1. The endothelial cells were incubated with increasing
concentrations of lipofectin for four hours. Antisense oligonucle-
otides inhibited the TNF-n induced ICAM-1 expression (P <
0.01) at all concentrations used, while reverse oligonucleotides
had only a minor, nonsignificant effect. At lipofectin concentra-
tions 0.1 to 0.5 mg/mg DNA, we observed only a slight, nonsigi-
ficant inhibition of TNF-a induced ICAM-1 expression, while
concentrations of 0.8 mgImgDNA inhibited ICAM-1 effectively.
Lipofectin at  2 mg/mg DNA damaged the cells. From these
experiments, a lipofectin concentration of 0.8 mg/mg DNA and a
ODN concentration of 2 mg/kg body wt was chosen for the in vitro
studies.
Figure 1A shows the effect of reverse and antisense oligonucle-
otides on expression of ICAM-1 in renal cortical vessels 24 hours
after 30 minutes of ischemia. The saline injected control showed
ICAM-1 staining along the vascular intima. This staining was
decreased in antisense ODN treated animals. The reverse ODN
treated animals, on the other hand, showed prominent ICAM-1
staining. Figure lB shows the corresponding densitometric anal-
ysis. Saline and reverse ODN treatment showed similar densities,
while the antisense ODN treated animals showed significantly less
ICAM-1 staining density.
Figure 2A shows the Western blotting of these same kidneys for
ICAM-l protein. Both the renal cortex and medulla from saline
treated and reverse ODN treated rats showed prominent amounts
of ICAM-1, while the antisense ODN treated animals showed
significantly less amounts of ICAM-1. Optical density (Fig. 2B)
illustrates the significant differences between these groups.
ICAM-1 expression in nonischemic sham operated, saline, or
lipofectin treated animals was not absent compared to unmanipu-
lated control rats. We observed a detectable increase in ICAM-1
expression in kidneys from these rats, indicating that the manip-
ulation itself up-regulates ICAM-1 (optical densities in arbitrary
units 11.9 1.3 vs. 8.5 1.7 in the medulla; 12.4 1.5 vs. 8.6
2.3 in the cortex). We found no difference between lipofectin and
saline treated, sham operated animals.
Figure 3 shows the effects on renal function. Creatinine (Fig.
3A) and urea (Fig. 3B) concentrations in serum increased by 12
hours and 24 hours in rats with ischemia treated with saline or
with reverse ODN, compared to rats given antisense ODN. Sham
operated rats had no increase in creatinine or urea concentra-
tions, compared either to baseline values or to values from
unmanipulated rats (not shown).
Figure 4A shows the effect on perivascular granulocyte infiltra-
tion at 12 hours as shown by immunohistochemistry. Saline-
treated ischemic rat kidneys showed considerable granulocyte
staining, which was more prominent than in the antisense ODN
group. Reverse ODN treatment, on the other hand, did not
ameliorate the granulocyte infiltration. Granulocyte infiltration
was found in only 23 vessels in antisense treated kidneys, com-
pared to 56 in untreated ischemic kidneys and 57 in kidneys
treated with reverse ODN (P < 0.05). We also quantified the
numbers of infiltrates (Fig. 4B). Granulocyte infiltrates were
significantly reduced by antisense treatment (P < 0.05), while
reverse ODN did not influence the ischemia-induced granulocyte
infiltration.
We conducted the same immunohistochemical staining and
quantitative evaluation for monocytes. Figure 5A shows the
monocyte perivascular staining in the renal cortex from ischemic
animals with saline, compared to antisense ODN treated animals
and reverse ODN treated animals. Monocytes around blood
vessels were more frequent in the saline and reverse ODN treated
sections, compared to the antisense ODN treated sections. Mono-
cyte infiltration was found in 39 vessels of antisense treated
kidneys, compared to 54 in untreated ischemic kidneys and 56 in
kidneys treated with reverse ODN (P < 0.05). We also quantified
the numbers of infiltrates (Fig. SB). Monocyte infiltrates were
significantly reduced by antisense treatment (P < 0.05), while
reverse ODN did not influence the ischemia-induced granulocyte
infiltration.
Representative hematoxylin and eosin renal cortical sections
from saline treated, antisense ODN treated, and reverse ODN
treated rats subjected to renal ischemia are shown in Figure 6.
Rats with saline treated (Fig. 6, left) and reverse ODN treated
(Fig. 6, right) renal ischemia showed moderate to severe necrosis.
The sections show tubular cell swelling, cellular vacuolization,
pyknotic nuclei, and round cell infiltration. Rats treated with
antisense ODN (Fig. 6, middle) showed prominent cell swelling
but only mild necrosis. Only a few pyknotic nuclei were observed,
and the round cell infiltration was less than in the other two
groups. Analysis of the grading scales revealed signficantly less
severe renal cortical damage in kidneys from antisense ODN
treated animals compared to the other two ischemic groups.
Discussion
We were successful in inhibiting ICAM-1 expression in endo-
thelial cells in vitro with antisense ODN [25]. We used these
results to estimate the lipofectin and antisense ODN concentra-
tions necessary to inhibit ICAM-1 expression in the rat with renal
ischemia. We found that antisense ODN indeed inhibited
ICAM-1 expression in vivo, and that it also ameliorated acute
renal failure according to functional and histological criteria. The
inhibited ICAM-1 expression was associated with decreased vas-
cular infiltration of both granulocytes and monocytes, which
supports the conclusion that adhesion molecules are important in
the genesis of ischemic acute renal failure. We believe that our
conclusions are supported by the fact that we showed the effect of
antisense treatment on ICAM-1 expression, production, and
effect in terms of leukocyte infiltration, as well as demonstrating
an effect on renal histology and function.
Our finding that ICAM-1 is important in reperfusion injury is
not new. Antibodies directed against ICAM-1 effectively block its
role in cell-to-cell adhesion and can ameliorate ischemic reperfu-
sion injury in several animal models [10, 15, 17, 18, 26—28]. A
modest but detectable up-regulation of ICAM-1 was present in
our sham operated rats, indicating the sensitivity of the cell-to-cell
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adhesion mechanism. However, our purpose was not to retest this
hypothesis. Instead, we sought to develop a novel, nonantibody
means of blocking ICAM-1 expression in vivo to specifically
ameliorate ischemic reperfusion injury. We used a phosphorothio-
ate-stabilized ODN against the 3' untranslated region of ICAM-1.
Bennett and coworkers have previously shown that antisense
ODN against this region are highly specific and very effective [25].
Furthermore, the antisense ODN selectively inhibited ICAM-1
expression while other endothelial adhesion molecules were not
affected [251. Our antisense ODN also inhibited TNF-a induced
ICAM-1 expression on the endothelial cell surface in vitro and
ischemia-induced up-regulation of ICAM-1 protein in vivo. The
inhibitory effect seems to involve RNase H hydrolysis of the target
mRNA [191. Experience with antisense technology is controversial
with regard to specificity of the inhibitory effect of phosphothi-
orate ODN [29]. Our results support the notion that phosphoro-
thioate ODN against endothelial adhesion molecules are a spe-
cific therapeutic tool.
To enhance ODN uptake we used the cationic lipid prepara-
tion, lipofectin. We established the optimal dose in the in vitro
Hailer et al: Antisense oligonucleotides for reperfusion injury 479
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Fig. 5. A. (opposite page, top) Immunohistochemical staining of ischemic
kidneys for monocytes (arrows on representative cells) with saline treatment
(left), antisense ODN treatment (middle), and reverse ODN treated animal
(right) (representative of 30 photo,nicrographs). B. The number of granulo-
cyte infiltrates qualitatively expressed as no infiltrates (s), ito 4 infiltrates(Li), or  5 infiltrates (•) from these immunohistochemical sections
(vessels counted N> 50; P < 0.05). Antisense ODN decreased monocyte
infiltration.
transplant medicine. In experimental animals, both renal isografts
and kidneys exposed to transient ischemia show a long-term
course of progressive proteinuria and gradual renal failure [32].
Thus, initial damage appears to foster a subsequent decline, even
if conventional rejection mechanisms are not involved. Cadaveric
donor kidneys are routinely stored in Collins or similar solutions
for 12 to 72 hours before transplantation.Delayed graft function
from ischemia and reperfusion injury is a major post-transplant
problem and has a direct negative impact on long-term graft
survival [33]. Transplanted hearts and livers also are subject to
reperfusion injury and ICAM-1 seems to play a role in acute and
chronic rejection [34—38]. The antisense ODN treatment could
avoid any potential immunological problems that might accom-
pany the use of antibodies directed against adhesion molecules,
particularly if the therapy is required more than once [20]. We
would envision a multiple antisense ODN treatment of transplant
grafts directed against a variety of adhesion molecules associated
with reperfusion injury and are currently pursuing experimental
studies of this nature. Finally, we believe the ODN approach
opens new avenues to investigate pathogenetic mechanisms in-
volved in acute renal failure and other renal diseases.
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Fig. 6. (opposite page, below) Hematoxylin and casio-stained thin sections
of fixed, paraffin-embedded, ischemic rat kidneys. Saline treatment (left),
antisense ODN treatment (middle) and reverse ODN treated animal
(right) (representative of 30 sections). Inflammatory infiltrate and tubular
necrosis manifest by swollen, vacuolated proximal tubular cells with
pyknotic nuclei, necrotic cells and loss of the basal lam ma, was diminished
by antisense ODN treatment. A quantitative grading scale verified these
findings.
experiments, but nevertheless included a sham operated lipofectin
control, since we had observed some renal damage from lipofectin
in earlier studies (unpublished observations). The low concentra-
tion of lipofectin used raises the question whether "naked" ODN
might have been successfully used to suppress protein expression
[20]. However, in preliminary experiments we were not able to
achieve significant inhibition of ICAM-1 without lipofectin in
vitro. Since lipofectin did exhibit some toxicity at higher doses, a
"concentration window" for the appropriate transfer enhance-
ment for antisense ODN in viva may be important. A detailed
consideration of vehicles in gene transfer is beyond the scope of
this discussion; however, we are evaluating liposomes with viral
fusion proteins as a potentially less toxic and more efficient
transfer approach.
We believe that the antisense approach to acute renal failure
and reperfusion injury could have clinical utility. We do not
envision prophylactic antisense ODN treatments in patients at
risk for acute renal failure. Prophyactic measures have been
employed in patients with ischemic acute renal failure and
patients at risk for iodinated contrast-induced acute renal failure.
The results have not been impressive [30, 31]. Instead, we believe
such an approach would be both more valuable and practical in
Reprint requests to Hermann HaIler, M.D., Franz Volhard Clinic, Wiltberg
Strasse 50, 13122 Berlin, Germany.
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